Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHRM 844 > Patho of Dyslipidemia > Flashcards

Patho of Dyslipidemia Flashcards

1
Q

Patho of Atherosclerosis

1) endothelial injury
2) ___ response
3) ___ infiltration
4) platelet adhesion
5) smooth muscle cell ___
6) extracellular ___ accumulation

A
  • inflammatory
  • macrophage
  • proliferation
  • matrix
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

T or F: dyslipidemia is largely asymptomatic

A

T
but depending on severity and duration of disease, the following can occur:
- chest pain
- palpitations
- sweating
- anxiety
- SOB
- Loss of consciousness
- difficulty with speech or movement
- abdominal pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Signs

  • we worry about ___ when TGs are over ___ - ___
  • eruptive ___
  • peripheral ___
  • increase BP
  • waist size greater than ___ in men and ___ in women
  • BMI greater than ___
A
  • pancreatitis, 400-500
  • xanthomas
  • polyneuropathy
  • BP
  • 40, 35
  • 30
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Lab Parameters

  • LDL- ___ - amount of cholesterol in LDL
  • LDL- ___ - number of LDL particles
  • Non-HDL-C: amount of cholesterol in atherogenic particles. non HDL-C = TC - HDL
  • Apo - ___ - number of atherogenic particles
A

C, P, B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Lab Parameters

ApoB, LDL-P, and non-HDL-C
- all valid in ___ sample and with elevated ___ levels
- all more predictive of future CVD risk than ___ alone

not routinely ordered

A
  • non-fasting
  • LDL-C
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is included in a FLP (4)

A
  • TC
  • TG
  • HDL-C
  • LDL-C
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Friedewald Equaton

used to estimate ___ from FLP
- not valid when TG > ___ mg/dL

LDL = ___

A

LDL
- 400
- TC - HDL - TG/5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

non-fastin sample: ___ and ___
TC:HDL goal ratio: less than or equal to ___ : ___
- optimal (___ - ___ :1)

A

TC, HDL
5:1
3-3.5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

LSM

  • ___ diet, USDA food pattern, AHA diet
  • reduce percent of calories for ___ and ___ fats (5-6% of calories from sat fats)
  • lower ___ intake ( < 1,000 mg/day)
  • moderate to vigorous aerobic physical activity
A
  • DASH
  • trans, saturated
  • sodium
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

____ kcal/1 gram of saturated fat

A

9

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Therapeutic Lifestyle Changes

  • soluble fiber to decrease ___
  • oat bran
  • pectins or gums
  • ___ products (binds cholesterol in gut and reduces hepatic production and clearance, 10-15 grams daily may decrease ___ and ___ by 20%)
A

LDL
psyllium
LDL, TC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Therapeutic Lifestyle Changes

  • Plant stanols and sterols (2-3 grams daily decreases ___ 6-15%) Example: ___
  • weight reduction
  • increased physical activity
  • smoking cessation
A

LDL
Benecol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Omega-3 Fatty Acids

Fish oil/Omega-3 fatty acids
- EPA/DHA
- reduces ___, may increase ___ by 4-49%

___ : 2-4 gms daily or divided BID
___ : 2 gms po BID with food
- IPE: only TG

IPE - icosapent ethyl

A

TG, LDL
Lovaza
Vascepa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

HMG-CoA Reductase inhibitors

  • Altoprev, Mevacor
  • Pravachol
  • Livalo
  • Zocor
  • Lescol
  • Lipitor
  • Crestor
A
  • lovastatin
  • pravastatin
  • pitavastatin
  • simvastatin
  • fluvastatin
  • atorvastatin
  • rosuvastatin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

High dose (mg) statin efficacy rank (most to least)

A

1) rosuvastatin (40 mg)
2) atorvastatin (80 mg)
3) simvastatin (40 mg or 80 mg)
4) pravastatin (80 mg) = lovastatin (80 mg) = pitavastatin (4 mg) = fluvastatin (80 mg)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Statin Intestity - Low

  • simvastatin ___ mg
  • pravastatin ___ - ___ mg
  • lovastatin ___ mg
  • fluvastatin ___ - ___ mg
A
  • 10 mg
  • 10-20 mg
  • 20 mg
  • 20-40 mg
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Statin Intestity - Mod

  • atorvastatin ___ - ___ mg
  • rosuvastatin ___ - ___ mg
  • simvastatin ___ - ___ mg
  • pravastatin ___ - ___ mg
  • lovastatin ___ - ___
  • fluvastatin ___ mg BID
  • fluvastatin XL ___ mg
  • pitavastatin ___ - ___ mg
A
  • 10-20 mg
  • 5-10 mg
  • 20-40 mg
  • 40-80 mg
  • 40-80 mg
  • 40 mg
  • 80 mg
  • 1-4 mg
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Statin Intestity - High

  • atorvastatin ___ - ___ mg
  • rosuvastatin ___ - ___ mg
A
  • 40-80 mg
  • 20-40 mg
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

which statins are hydrophylic and will not cross BBB (2)

A
  • pravastatin
  • rosuvastatin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

which statins are metabolized by CYP3A4 (3)

A
  • lovastatin
  • simvastatin
  • atorvastatin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Statin Clinical Trials

1) IMPROVE-IT
2) SEARCH

A

1) zetia + statin = good. reduced CV events and lowered LDL
2) simvastatin 80 mg shouldnt be started in new patients bc of myopathy. Can only be used if patient has been on it for awhile and are fine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Statins: Important Considerations

  • obtain LFTs at baseline, repeat when clinically indicated, DC if LFTs are ___ x upper limit normal
  • myopathy/rhabdomyolysis
  • muscle pain and ___ urine
  • avoid grapefruit juice (> 1 ___ )
  • contraindicated in pregnant women
A

3
dark
quart

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

characteristric predisposing to statin side effects

  • impaired renal or hepatic function
  • prior statin intolerance or ___ disorders
  • unexplained ALT elevations greater than ___ x upper limit normal
  • other drugs that affect statin metabolism
  • > ___ years of age
A
  • hepatic, renal
  • muscle
  • 3
  • 75
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Muscle pain on statins

  • ___ statin and evaluate for rhabdomyolysis
  • evaluate for exacerbating conditions
  • restart same for lower dose once symptoms resolve
A

DC

25
Q

Statin Contraindications

  • acute ___ disease
  • unexplained, persistent elevations of serum ___
  • ____ and ____
A
  • liver
  • transaminases
  • pregnancy, breastfeeding
26
Q

Statins and Muscle Injury

  • muscle injury is ___ with statin monotherapy
  • may experience myalgias without elevated ___ ___ . (> 10x upper limit of normal: ___ statin)
  • risk of muscle injury is increased when taking statins extensively metabolized by ___ and drugs that interfere with ____
A
  • uncommon
  • creatine kinase, DC
  • CYP3A4, CYP3A4
27
Q

T or F: if patient experiences muscle pain, switch to lipophilic statin

A

FALSE, hydrophylic

cannot cross BBB

28
Q

Statin Alternative dosing

  • to improve utilization or tolerability and decrease cost: every ___ day and once ___ dosing
  • intitial data for ___, ___, and ___ suggest that ___ the daily dose if necessary for every ___ day to achieve similar LDL lowering
A
  • other, weekly
  • fluvastatin, atorvastatin, rosuvastatin, double, other
29
Q

Simvastatin Considerations

Contraindicated drugs (11)

A
  • itraconazole
  • ketoconazole
  • posaconazole
  • erythromycin
  • clarithromycin
  • telithromycin
  • HIV protease inhibitors
  • nefazodone
  • gemfibrozil
  • cyclosporine
  • danazol
30
Q

Simvastatin Considerations

do not exceed 10 mg simvastatin daily with (2)

A
  • verapamil
  • diltiazem
31
Q

Simvastatin Considerations

do not exceed 20 mg simvastatin daily with (3)

A
  • amiodarone
  • amlodipine
  • ranolazine
32
Q

Statins and hyperglycemia

JUPITER - 27% increase in reported ___ (rosuvastatin vs placebo)
PROVE-IT TIMI 22 - ___ leading to worse glycemic control

Takeaways: benefits still outweigh risks

A

diabetes
atorvastatin

33
Q

Statin Monitoring

FLP
- baseline
- ___ - ___ weeks following statin initiation
- every ___ - ___ months, as clinically indicated (insurance typically only allows ___ )

Consider
- baseline ___ in individuals with increased risk of adverse muscle effects
- ___ while on statin therapy in individuals with ___ symptoms
- ___ function in individuals with symptoms of ___

A
  • 4-12
  • 3-12, yearly
  • CK
  • CK
  • hepatic, hepatotoxicity
34
Q

Bile Acid Resins

  • ___ (Questran, Prevalite)
  • ___ (Colestid)
  • Colesevelam ( ___ )
A
  • cholestyramine
  • colestipol
  • WelChol
35
Q

Bile Acid Resins

decrease ___ and ___

disadvantages:
- may increase ___
- take other medications ___ hr before or ___ hr after BAR

GI side Effects: constipation, bloating, nausea, flatulence

Adverse Effects:
- impaired adsorption of ___ soluble vitamins ___ , ___ , ___ , and ___
- ___ natremia
- ___ chloremia
- ___ obstruction

can also be used as a stool softener

A
  • LDL, Cholesterol
  • TG
  • 1, 4
  • fat, A, D, E, K
  • hypernatremia
  • hyperchloremia
  • GI
36
Q

BAR Contraindicatoins

Cholestyramine
- complete ___ obstruction

Colesevelam
- Hx of ___ obstruction
- serum TG > ___ mg/dL
- Hx of ___ induced pancreatitis

A
  • biliary
  • bowel
  • 500
  • hypertriglyceridemia
37
Q

BAR Interactions

may decrease effect of (9)

A
  • acetaminophen
  • TzDs
  • OC
  • corticosteroids
  • ezetimide
  • fibrated
  • thiazide diuretics
  • warfarin
  • digoxin
38
Q

Niacin (Niacor, Niaspan, Slo-Niacin)

OTC
- not federally regulated
- some marked no flush, do not have free ___ and are ineffective in treating dyslipidemia
- ___ release assocaited with increased risk of hepatotoxicity

Prostaglandin mediated flushing and itching
- administer ___ 325 mg 30 min before taking
- take close to ___ times
- avoid alcohol and hot drinks (worsen flushing)
- increase ___
- hyper ___ and hyper ___
- may increase levels of ___

A
  • nicotinic acid
  • sustained
  • ASA
  • meal
  • LFT
  • hyperglycemia, hyperuricemia
  • statins
39
Q

Niacin Contraindications

  • active ___ disease
  • significant/unexplained persistent liver ___ elevations
  • active ___
  • arterial ___
A
  • hepatic
  • transaminase
  • peptic ulcer
  • hemorrhage
40
Q

Niacin Clinical Trials

  • Coronary Drug Project (CDP)
  • ARBITER 6-HALTS
  • AIM-HIGH
  • HPS2-THRIVE

takeaways: is there a benefit to adding niacin? ___

A

NO

41
Q

Chlesterol Absorption inhibitor

Ezetimibe (Zetia)
- combination product with ___ (Vytorin)
- can further decrease ___ by 12-20% when combined with statins

A

simvastatin
LDL

42
Q

Chlesterol Absorption inhibitor

Ezetimibe
AE (3)
Contraindications
- concomitant use with a __ and active ___ disease or ___ elevations
- pregnancy and breast feeding when used concomitantly with ___

A
  • fatigue, diarrhea, GI upset
  • statin, hepatic, transaminase
  • statin
43
Q

Exetimibe Clinical trials

  • ENHANCE
  • SHARP
  • IMPROVE-IT
  • EWTOPIA 75
    Takeaways: ezetimbibe will reduce ___ events when combined with ___
A

CV, statins

44
Q

Fibrates

SE:
- GI disturbances
- Rash
- myalgia
- dizziness

Contraindications
- Hx of ___ disease
- ___ or dialysis
- persistnet ___ disease

A
  • gallbladder
  • ESRD
  • liver
45
Q

Fibrates increase levels of these 4 drugs…

A
  • statins
  • ezetimibe
  • SUs
  • warfarin
46
Q

Fibrate Clinical Trials

  • ACCORD Lipid: no increased benfit
  • FIELD: reduced nonfatal MI only in T2DM
  • VA-HIT: CHD events reduced by 11% with gemfibrozil for very 5 mg/d: increase in HDL
A

eh

47
Q

PSCK9 Monoclonal Antibodies

Alirocumab ( ___ ) and ___ (Repatha)
- Indications: reduce LDL in familial ___ hypecholesterolemia or ASCVD
- MOA: inhibits binding of PSCK9 to ___ recptors and upregulates the recycling of ___ , resulting in a drastic decrease in ___
- AE: GI upset, increase ___ , injection site rxn, myalgia, flu like symptoms

A

Praluent, evolocumab
- heterozygous
- LDL, LDL-R, LDL
- LFTs

48
Q

PCSK9 mAbs should be considered for…

  • ASCVD risk reduction on max tolerated statin therapy with or without ezetimibe, and LDL-C greater than ___ or non-HDL-C greater than ___
  • very high risk/ statin intolerance
  • Further reduction of LDL-C if pretreatment LDL-C is greater than ___ (on max statin and ezetimibe)
A
  • 70, 100
  • 190
49
Q

Odyssey Outcomes Trial

Intervention: Alirocumab lowered major adverse ___ events, lowered ___

A

cardiac, LDL

50
Q

Inclisiran ( ___ )

  • Lowers ___ and ___
  • indicated for ___ hypercholesterolemia or ___
  • MOA: long acting synthetic ___ that inhibits translocation of ___ protein thus inhibits its production. Prolongs activity of ___ receptors
  • initial dose, 2nd dose ___ months later, then ___ months later

AE:
- inj site reactions
- arthralgia
- UTI
- diarrhea
- bronchitis
- pain in extremities
- dyspnea

A

Leqvio
- LDL, cholesterol
- heterozygous, ASCVD
- siRNA, PCSK9, LDL
- 3, 6

51
Q

ORION Trials

  • ORION 9, 10 and 11: lowers LDL really well (39.7%, 52.3% and 49.9% compared to placebo)
  • ORION 5 - evaluating efficacy in ___ familial hypercholesterolemia
  • ORION 4 - evaluating efficacy in ___
A
  • homozygous
  • ASCVD
52
Q

Bempedoic Acid

Brand: ___ , ___
- indication: adjunt to diet and statin to reduce ___ in familial ___ hypercholesterolmia or ___
- MOA: inhibits ___
- AE: URTI, muscle spasms, hyperuricemia, back pain, abdominal pain, bronchitis, pain in extremity, anemia, and elevated liver enzymes
- Warnings and Precautions: may increase blood uric acid levels and lead to the development of ___
- risk of ___ rupture
- avoid concomitant use with ___ > 20 mg and ____ > 40 mg (myopathy)

A

Nexletol, Nexlizet
- LDL, heterozygous, ASCVD
- ACLY
- gout
- tendon
- simvastatin, pravastatin

53
Q

Bempedoic acid Clinical trials

CLEAR TRANQUILITY
CLEAR HARMONY CLEAR SERENITY
CLEAR WISDOM
CLEAR OUTCOMES

Works well

A
54
Q

addition medications

red yeast rice
- active ingredient: ___
- shown to lower ___ , ___ , and ___ as well as __- events, and possible increase ___
- same AE and interactions as statins
- no standardization

A

lovastatin
- TC, LDL-C, TG, CV, HDL

55
Q

Additional Medications

lomitapide ( ___ )
- microsomal ___ transfer protein inhibitor ( ___ )
- indicated as adjunct to low fat diet and other lipid lowering treatments to reduce ___ , ___ , ___ , and ___ in patients with ___ familial hypercholesterolemia
- boxed warning for ___
- only available through ___ program

A

Juxtapid
- triglyceride (MTTP-I)
- LDL, TG, ApoB, non-HDL-C, homozygous
- hepatotoxicity
- REMS

56
Q

Lomitapide Mechanism

1) directly binds and inhibits ___ ___ ___ ___ (MTP), therby preventing the assembly of ___ containing lipoproteins in enterocytes and hepatocytes
2) inhibits the synthesis of ___ and ___
3) leads to reduced levels of plasma LDL-C

A
  • microsomal triglyceride transfer protein, ApoB
  • chylomicrons, VLDL
57
Q

evinacumab MOA

binds to and inhibits ___ (angiopoietin-like protein 3) and rescues/allows ___ and ___ to promote ___ processing and clearance from ___ formation

A
  • ANGPTL3
  • LPL, EL, VLDL, LDL
57
Q

Additional Medications

evinacumab ( ___ )
- recombinant human monoclonal antibody indicated as an adjunct therapy to other lipid lowering therapies to reduce ___ in adults AND ___ patients greater than ___ yo with ___ familial hypercholesterolemia
- ___ infusion once ___

A

Evkeeza
LDL-C, pediatric, 12
homozygous
- IV, monthly

PHRM 844 (52 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions